This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Short Bowel Syndrome (SBS)

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Sponsored by Takeda

About this trial

Last updated 2 months ago

Study ID

TAK-633-4006

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 months ago

What is this trial about?

The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada. This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study. The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.

What are the participation requirements?

Yes

Inclusion Criteria

Must be 18 years or older at first dose of teduglutide
Must be diagnosed with intestinal failure due to short bowel syndrome (SBS-IF) because of intestinal resection.
Must have been dependent on parenteral support before teduglutide treatment.
Must have been treated with teduglutide and followed up for at least 6 months.

Additional entry criteria will be discussed with the study doctor.

Locations

Location

Status

Recruiting

For more information, view the full study details:

NCT05371028